	US 12,435,123 B2
	Immunotherapies using enhanced iPSC derived effector cells
Bahram Valamehr, San Diego, CA (US); Ryan Bjordahl, San Diego, CA (US); and Tom Tong Lee, San Diego, CA (US)
Assigned to FATE THERAPEUTICS, INC., San Diego, CA (US)
Appl. No. 17/297,805
Filed by FATE THERAPEUTICS, INC., San Diego, CA (US)
PCT Filed Nov. 25, 2019, PCT No. PCT/US2019/063024 § 371(c)(1), (2) Date May 27, 2021, PCT Pub. No. WO2020/117526, PCT Pub. Date Jun. 11, 2020.
Claims priority of provisional application 62/774,278, filed on Dec. 2, 2018.
Prior Publication US 2022/0127328 A1, Apr. 28, 2022
Int. Cl. C07K 14/705 (2006.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); C12N 5/0783 (2010.01); C12N 15/90 (2006.01)

CPC C07K 14/7056 (2013.01) [A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); C12N 5/0636 (2013.01); C12N 5/0646 (2013.01); C12N 15/907 (2013.01); C12N 2506/45 (2013.01); C12N 2510/00 (2013.01)]

28 Claims

1. A cell or a population thereof, wherein

(i) the cell is (a) an immune effector cell, (b) an induced pluripotent cell (iPSC), or (c) a derivative cell obtained from differentiating the cell of (b);

(ii) the cell comprises a cell genome and an exogenous polynucleotide encoding NKG2C; and

(iii) the exogenous polynucleotide encoding NKG2C is (a) integrated in the cell genome at a position other than that of an endogenous NKG2C, (b) comprised in a non-chromosomal polynucleotide, or (c) comprised in a polynucleotide having a sequence that is not native to the cell.